

The Predictability Premium

BUILDING STABLE GROUND FOR REMS

Elaine Lippmann, J.D.

March 12, 2026

LEAVITT
PARTNERS
An HMA Company



Outline

Current Regulatory Environment

RIC's Role in Policy Development

Proposed Examples

Case Studies

Discussion

Current Regulatory Environment



Current Regulatory Environment



Turmoil at FDA

- Staffing Shortage
- Leadership Changes
- Podium Policy/Unconventional Approach
- Emphasis on One-Off Deals


Why Stability Matters

Consistency

Rely on prior positions when designing programs

Predictability

Reduce risk of late-stage requirement shifts



Uncertainty Hits Close to Home

- Staffing shortages might mean longer timelines, inconsistent feedback
- Increased political influence – will use of REMS authority expand?
- Leadership willingness to stretch legal authority

The Ongoing Uncertainty Struggle



Industry Challenges

- Submission delays for unknown reasons
- Not knowing whether Agency will accept new idea
- Fear that small changes might trigger larger modification

Agency Reality

- Proposals have cross-program implications
- Precedent concerns
- Novel legal complexities



RIC can counter
uncertainty with
policy strategy




Laying a foundation for the long term

Collaborate, Standardize, Innovate to Modernize REMS



COLLABORATE




STANDARDIZE




INNOVATE

Collaborate, Standardize, Innovate to Modernize REMS



Examples





Example #1: Sharing Innovation Successes




Assessment shows risk was successfully managed through a particular physician training method

You share method with others, and they use that info to improve their own program


These successes persuade FDA to adopt more standardized approach to prescriber training for a particular type of risk

Time spent on tech solutions instead of back-and-forth with FDA

Innovative tech solutions benefit entire industry



Example #2: Engagement with Stakeholders in Health Care System





Example #3

Tech Advancement in REMS



Review FDA's General AI Guidance and extrapolate to REMS context

Develop consensus on use cases, specific tools, and validation methods

Present AI REMS capabilities to FDA as united voice





Example #4

Explore Legislative Solutions both Agency and Industry can Support



Data Standards

FDA can require use of established data standards



More Specificity in Requirements

FDA can be more proscriptive, and industry has clearer expectations



Pilots

For things like mobile apps and smart devices



Case Studies





Case Study: Seeking Standardization for Patient-Reported Outcomes

Before FDA guidance, acceptance of PRO was highly variable.

Industry advocacy through trade group sought:

- Clear evidentiary criteria
- Predictable expectations
- Early engagement pathways

Resulting guidance is strict, but provides written standards, common language, and transparency

Case Study:


Learning from Drug Shortages

FDA had assumptions about manufacturing:

- Commercial scale similar to clinical scale
- Tight control over post-approval changes does not affect supply

Meetings following drug shortages educated FDA:

- Process must evolve as scale increases
- Freezing manufacturing processes early leads to fragility
- Global supply chains don't behave like single-site models



Guiding Principles Behind These Examples



Bringing requests as system-level problems, not product-specific exceptions

Asking for standards, not leniency

Showing you understand FDA's internal constraints

Educating the Agency



Collaborate
Invest time into
broad policy
solutions




Innovate
Less iteration =
more time for
innovation

Standardize
Educate Agency
and advocate for
consistency



Challenge Creating Opportunity



Q&A



202-774-1566



www.leavittpartners.com



@LeavittPartners